Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets
Authors:
- 2 June 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (7) , 2436-2443
Abstract
The therapeutic equivalence of generic and brand name antiepileptic drugs has been questioned by neurologists and the epilepsy community. A potential contributor to such concerns is pharmaceutical quality. The objective was to assess the biopharmaceutic risk of brand name Lamictal 100 mg tablets and generic lamotrigine 100 mg tablets from several manufacturers. Lamotrigine was characterized in terms of the Biopharmaceutics Classification System (BCS), including aqueous solubility and Caco-2 permeability. A panel of pharmaceutical quality tests was also performed on three batches of Lamictal, three batches of Teva generic, and one batch of each of four other generics: appearance, identity, assay, impurity, uniformity of dosage units, disintegration, dissolution, friability, and loss on drying. These market surveillance results indicate that all brand name and generic lamotrigine 100 mg tablets passed all tests and showed acceptable pharmaceutical quality and low biopharmaceutic risk. Lamotrigine was classified as a BCS class IIb drug, exhibiting pH-dependent aqueous solubility and dissolution. At pH 1.2 and 4.5, lamotrigine exhibited high solubility, whereas lamotrigine exhibited low solubility at pH 6.8, including non-sink dissolution. Lamotrigine showed high Caco-2 permeability. The apparent permeability (Papp) of lamotrigine was (73.7 ± 8.7) × 10–6 cm/s in the apical-to-basolateral (AP–BL) direction and (41.4 ± 1.6) × 10–6 cm/s in the BL–AP direction, which were higher than metoprolol’s AP–BL Papp of (21.2 ± 0.9) × 10–6 cm/s and BL–AP Papp of (34.6 ± 4.6) × 10–6 cm/s. Overall, lamotrigine’s favorable biopharmaceutics from a drug substance perspective and favorable quality characteristics from a tablet formulation perspective suggest that multisource lamotrigine tablets exhibit a low biopharmaceutic risk.Keywords
Funding Information
- U.S. Food and Drug Administration (HHSF223201010144A)
This publication has 20 references indexed in Scilit:
- Comparison of the Permeability of Metoprolol and Labetalol in Rat, Mouse, and Caco-2 Cells: Use as a Reference Standard for BCS ClassificationMolecular Pharmaceutics, 2013
- Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeabilityEpilepsia, 2010
- Generic substitution in the treatment of epilepsy: Patient and physician perceptionsEpilepsy & Behavior, 2008
- Generic Antiepileptic Drugs: Current Controversies and Future DirectionsEpilepsy Currents, 2008
- Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue?Epilepsia, 2007
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic DrugsEpilepsia, 2006
- Characterization of Dexloxiglumide in vitro Biopharmaceutical Properties and Active TransportJournal of Pharmaceutical Sciences, 2003
- Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification systemInternational Journal of Pharmaceutics, 2000
- A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo BioavailabilityPharmaceutical Research, 1995